Nyrada (ASX:NYR) Total Premiums Earned

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:NYR Nyrada Inc ASX:NYR
18 GF Score
Price A$0.60
! 1 Warning Sign
View Full Analysis

What is Nyrada Total Premiums Earned?

Total Premiums Earned only applies to insurance companies.

ASX:NYR
18GF Score
Nyrada Inc ASX:NYR
Total Premiums Earned is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nyrada Business Description

Address 180 George Street, Sydney Place, Level 22/23, Salesforce Tower, Sydney, NSW, AUS, 2000
Nyrada Inc is an Australian clinical-stage biotechnology company focused on discovering and developing small-molecule therapeutics. Its research centres on inhibitors of Transient Receptor Potential Canonical (TRPC) ion channels, with its lead candidate, Xolatryp, being developed for cardioprotection and neuroprotection applications, including the prevention of damage following ischemic events. The company operates as a single business segment, pharmaceutical research and development, and conducts its activities primarily in Australasia. As a clinical-stage company, Nyrada does not generate product revenue; it funds its research and development programs through equity capital raised from investors and, where applicable, research grants and collaboration arrangements. Its customers, in the commercial sense, are ultimately healthcare providers and patients who would use any approved therapies, while its nearer-term stakeholders include shareholders and research partners supporting its drug development pipeline.
18GF Score

Get the complete analysis for ASX:NYR

Total Premiums Earned is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.60
Price